Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 115-123

  Hall, Belinda S ^a,b   Wilkinson, Shane R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 2 NITROIMIDAZOLE; 4 NITROIMIDAZOLE; 4,5 DIHYDRO 4,5 DIHYDROXYIMIDAZOLE; BENZNIDAZOLE; HYDROXYL GROUP; HYDROXYLAMINE; IMIDAZOLE DERIVATIVE; METRONIDAZOLE; NIMORAZOLE; NITROREDUCTASE; PIMONIDAZOLE; SECNIDAZOLE; TINIDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVATION; DRUG METABOLISM; DRUG PROTEIN BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

BIOTRANSFORMATION; CHAGAS DISEASE; CHROMATOGRAPHY, LIQUID; DNA DAMAGE; GLYOXAL; GUANOSINE; HUMANS; HYDROXYLAMINE; IMIDAZOLES; KINETICS; MASS SPECTROMETRY; NAD; NITROIMIDAZOLES; NITROREDUCTASES; PRODRUGS; PROTOZOAN PROTEINS; SPECTROPHOTOMETRY; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 84455170162     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05135-11     Document Type: Article

References (53)

1. Alsford S, Kawahara T, Glover L, Horn D. 2005. Tagging a T. brucei rRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol. Biochem. Parasitol. 144:142-148. (Pubitemid 41572220)
2. Baker N, Alsford S, Horn D. 2011. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 176:55-57.
3. Bern C, Montgomery SP. 2009. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49:e52-e54.
4. Buschini A, et al. 2009. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. J. Parasitol. Res. 2009:463575.
5. Castro JA, de Mecca MM, Bartel LC. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25:471-479. (Pubitemid 44384589)
6. Chauhan SC, Padmanabhan PK, Madhubala R. 2008. Glyoxalase pathway of trypanosomatid parasites: a promising chemotherapeutic target. Curr. Drug Targets 9:957-965.
7. Dufernez F, et al. 2006. The presence of four iron-containing superoxide dismutase isozymes in trypanosomatidae: characterization, subcellular localization, and phylogenetic origin in Trypanosoma brucei. Free Radic. Biol. Med. 40:210-225. (Pubitemid 43069347)
8. Goodwin A, et al. 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:383-393. (Pubitemid 28182260)
9. Greig N, Wyllie S, Patterson S, Fairlamb AH. 2009. A comparative study of methylglyoxal metabolism in trypanosomatids. FEBS J. 276:376-386.
10. Greig N, Wyllie S, Vickers TJ, Fairlamb AH. 2006. Trypanothione-dependent glyoxalase I in Trypanosoma cruzi. Biochem. J. 400:217-223. (Pubitemid 44852035)
11. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286:13088-13095.
12. Hall BS, Wu X, Hu L, Wilkinson SR. 2011. Exploiting the drugactivating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54:1193-1199.
13. Heimbrook DC, Sartorelli AC. 1986. Biochemistry of misonidazole reduction by NADPH-cytochrome c (P-450) reductase. Mol. Pharmacol. 29:168-172. (Pubitemid 16165851)
14. Hirumi H, Hirumi K. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989. (Pubitemid 20099178)
15. Hrdy I, Cammack R, Stopka P, Kulda J, Tachezy J. 2005. Alternative pathway of metronidazole activation in Trichomonas vaginalis hydrogenosomes. Antimicrob. Agents Chemother. 49:5033-5036. (Pubitemid 41778917)
16. Kedderis GL, Argenbright LS, Miwa GT. 1989. Covalent interaction of 5-nitroimidazoles withDNAand protein in vitro: mechanism of reductive activation. Chem. Res. Toxicol. 2:146-149. (Pubitemid 19159942)
17. Kendall G, Wilderspin AF, Ashall F, Miles MA, Kelly JM. 1990. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase does not conform to the 'hotspot' topogenic signal model. EMBO J. 9:2751-2758.
18. Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchene M. 2007.Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol. 5:e211.
19. Marczak R, Gorrell TE, Muller M. 1983. Hydrogenosomal ferredoxin of the anaerobic protozoon, Tritrichomonas foetus. J. Biol. Chem. 258:12427-12433.
20. Marin-Neto JA, et al. 2009. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz 104(Suppl. 1):319-324.
21. Mason RP, Holtzman JL. 1975. The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry 14:1626-1632.
22. Maya JD, et al. 2003. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol. 65:999-1006. (Pubitemid 36293683)
23. McCalla DR. 1983. Mutagenicity of nitrofuran derivatives: review. Environ. Mutagen. 5:745-765.
24. McCalla DR, Reuvers A, Kaiser C. 1971. Breakage of bacterial DNA by nitrofuran derivatives. Cancer Res. 31:2184-2188.
25. Mitchel RE, Birnboim HC. 1977. The use of Girard-T reagent in a rapid and sensitive methods for measuring glyoxal and certain other alphadicarbonyl compounds. Anal. Biochem. 81:47-56. (Pubitemid 8141266)
26. Moreno SN, Docampo R. 1985. Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis. Environ. Health Perspect. 64:199-208. (Pubitemid 16135790)
27. Moreno SN, Docampo R, Mason RP, Leon W, Stoppani AO. 1982. Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations. Arch. Biochem. Biophys. 218:585-591. (Pubitemid 13192568)
28. Murta SM, et al. 2008. Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Trop. 107:59-65.
29. Nivinskas H, et al. 2001. Quantitative structure-activity relationships in two-electron reduction of nitroaromatic compounds by Enterobacter cloacae NAD(P)H:nitroreductase. Arch. Biochem. Biophys. 385:170-178. (Pubitemid 32988995)
30. Nogueira FB, et al. 2006. Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. 100:119-132. (Pubitemid 44821036)
31. Olekhnovich IN, Goodwin A, Hoffman PS. 2009. Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of Helicobacter pylori. FEBS J. 276:3354-3364.
32. Panicucci R, McClelland RA. 1989. 4,5-Dihydro-4,5-dihydroxyimidazoles as products of the reduction of 2-nitroimidazoles. HPLC assay and demonstration of equilibrium transfer of glyoxal to guanine. Can. J. Chem. 67:2128-2135. (Pubitemid 20116693)
33. Perez-Reyes E, Kalyanaraman B, Mason RP. 1980. The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol. Pharmacol. 17:239-244. (Pubitemid 10125311)
34. Peterson FJ, Mason RP, Hovsepian J, Holtzman JL. 1979. Oxygensensitive and-insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014.
35. Prathalingham SR, Wilkinson SR, Horn D, Kelly JM. 2007. Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrob. Agents Chemother. 51:755-758. (Pubitemid 46185302)
36. Raleigh JA, Koch CJ. 1990. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40:2457-2464.
37. Silver AR, McNeil SS, O'Neill P, Jenkins TC, Ahmed I. 1986. Induction of DNA strand breaks by reduced nitroimidazoles. Implications for DNA base damage. Biochem. Pharmacol. 35:3923-3928. (Pubitemid 17186133)
38. Sokolova AY, et al. 2010. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54:2893-2900.
39. Stover CK, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966. (Pubitemid 30435054)
40. Stuart K, et al. 2008. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Investig. 118:1301-1308.
41. Temperton NJ, Wilkinson SR, Meyer DJ, Kelly JM. 1998. Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocidal agents gentian violet and benznidazole. Mol. Biochem. Parasitol. 96:167-176. (Pubitemid 28511032)
42. Thornalley PJ. 1990. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem. J. 269:1-11. (Pubitemid 20210831)
43. Thornalley PJ. 2008. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease. Drug Metabol. Drug Interact. 23:125-150. (Pubitemid 351669568)
44. Varghese AJ, Whitmore GF. 1983. Modification of guanine derivatives by reduced 2-nitroimidazoles. Cancer Res. 43:78-82. (Pubitemid 13172798)
45. Varghese AJ, Whitmore GF. 1985. Properties of 2-hydroxylaminoimidazoles and their implications for the biological effects of 2-nitroimidazoles. Chem. Biol. Interact. 56:269-287. (Pubitemid 16173395)
46. Walton MI, Workman P. 1987. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem. Pharmacol. 36:887-896. (Pubitemid 17038036)
47. Wardman P. 1985. Some reactions and properties of nitro radical-anions important in biology and medicine. Environ. Health Perspect. 64:309-320. (Pubitemid 16135799)
48. Wendler A, Irsch T, Rabbani N, Thornalley PJ, Krauth-Siegel RL. 2009. Glyoxalase II does not support methylglyoxal detoxification but serves as a general trypanothione thioesterase in African trypanosomes. Mol. Biochem. Parasitol. 163:19-27.
49. West SB, et al. 1982. Drug residue formation from ronidazole, a 5-nitroimidazole. I. Characterization of in vitro protein alkylation. Chem. Biol. Interact. 41:265-279. (Pubitemid 12052470)
50. Whitmore GF, Varghese AJ. 1986. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. Pharmacol. 35:97-103. (Pubitemid 16161371)
51. Whitmore GF, Varghese AJ, Gulyas S. 1986. Reaction of 2-nitroimidazole metabolites with guanine and possible biological consequences. IARC Sci. Publ. 1986:185-196.
52. Wilkinson SR, et al. 2006. Functional characterisation of the iron superoxide dismutase gene repertoire in Trypanosoma brucei. Free Radic. Biol. Med. 40:198-209. (Pubitemid 43069346)
53. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027. (Pubitemid 351738503)